echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > European Radiology: Prediction by CT radiomics of recurrence-free survival after gallbladder cancer

    European Radiology: Prediction by CT radiomics of recurrence-free survival after gallbladder cancer

    • Last Update: 2022-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Gallbladder cancer (GBC) is the most common biliary malignancy, accounting for 80-95%
    of biliary malignancies.
    At present, radical resection is still the most effective
    treatment
    .
    However,
    some patients with GBC often experience recurrence and metastasis
    even after radical surgery.
    According to statistics, about 30-50% of patients will experience recurrence
    within 5 years after surgical resection.

    Postoperative adjuvant chemoradiotherapy is an important treatment option
    for patients at high risk of recurrence.
    Therefore, reliable prognostic markers are needed to
    identify patients at high risk of recurrence and optimize personalized treatment decisions
    .

    Radiomics, which transforms qualitative, raw medical images into quantitative, mineable data, is gaining increasing clinical attention
    .
    Radiomics has been reported to be a reliable predictive method
    for GBC patients.
    However, to our knowledge, no radiomic analysis
    for GBC recurrence prediction has been found.

    Recently, a study published in the journal European Radiology developed a radiomic feature based on preoperative enhanced CT to predict recurrence-free survival (RFS) of GBC patients, and further constructed a nomogram model for predicting individual RFS by integrating clinicopathological factors and radiomic features, which provides imaging support
    for accurate and non-invasive evaluation of the prognosis of GBC patients before clinical surgery.

    This study retrospectively included 204 consecutive patients with pathologically diagnosed GBC and randomized to development (n = 142) and validation (n = 62) (7:3).

    The radiomic features of
    the tumor in each patient were extracted from preoperative contrast-enhanced CT imaging.
    In the development cohort, the minimum absolute contraction and selection operator (LASSO) Cox regression method was used to develop radiomic features
    predicted by RFS.
    Based on the median radiomics score, patients are stratified into high or low groups
    .
    A nomogram model was established by incorporating important pathological predictors and radiomic features and using multivariate Cox regression.

    Radiomic features based on 12 features can distinguish high-risk patients
    with poor RFS.
    Multivariate Cox analysis showed that pT3/4 (hazard ratio, [HR]=2.
    691), pN2 (HR=3.
    60), poor differentiation (HR=2.
    651), and high radiomics score (HR=1.
    482) were independent risk variables associated with poor RFS and were included in the construction nomination plot
    .
    The nomination plot
    shows good predictive performance in evaluating RFS, with AUC values of 0.
    895, 0.
    935 and 0.
    907
    for 1, 3 and 5 years, respectively.


    Figure
    a Establish decision trees and stratify patients into three risk subgroups
    .
    b Relapse-free survival differs significantly between the three risk subgroups

    In this study, the radiomic features for predicting GBC RFS were developed and extracted according to preoperative contrast-enhanced CT, and a nomogram to optimize the risk stratification and individualized risk prediction of RFS was established by combining it with pathological factors, which could realize the non-invasive early identification of high-risk GBC patients and promote the formulation
    of personalized treatment plans for GBC patients.

    Original source:

    Fei Xiang,Xiaoyuan Liang,Lili Yang,et al.
    Contrast-enhanced CT radiomics for prediction of recurrence-free survival in gallbladder carcinoma after surgical resection.
    DOI:10.
    1007/s00330-022-08858-5

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.